NASDAQ:CGEM - Nasdaq - US2300311063 - Common Stock - Currency: USD
7.9
+0.15 (+1.87%)
The current stock price of CGEM is 7.9 USD. In the past month the price increased by 4.36%. In the past year, price decreased by -72.13%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.84 | 342.32B | ||
AMGN | AMGEN INC | 14.56 | 155.14B | ||
GILD | GILEAD SCIENCES INC | 13.46 | 129.91B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1736.21 | 129.44B | ||
REGN | REGENERON PHARMACEUTICALS | 12.47 | 62.19B | ||
ARGX | ARGENX SE - ADR | 331.32 | 38.44B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.46B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.92B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.00B | ||
NTRA | NATERA INC | N/A | 20.94B | ||
BIIB | BIOGEN INC | 7.3 | 17.59B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.42B |
Cullinan Therapeutics, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 111 full-time employees. The company went IPO on 2021-01-08. The company has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.
CULLINAN THERAPEUTICS INC
One Main Street, Suite 1350
Cambridge MASSACHUSETTS 02142 US
CEO: Owen Hughes
Employees: 111
Company Website: https://cullinantherapeutics.com/
Investor Relations: http://cullinanoncology.com/investors-overview/
Phone: 16174104650
The current stock price of CGEM is 7.9 USD. The price increased by 1.87% in the last trading session.
The exchange symbol of CULLINAN THERAPEUTICS INC is CGEM and it is listed on the Nasdaq exchange.
CGEM stock is listed on the Nasdaq exchange.
16 analysts have analysed CGEM and the average price target is 32.81 USD. This implies a price increase of 315.32% is expected in the next year compared to the current price of 7.9. Check the CULLINAN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CULLINAN THERAPEUTICS INC (CGEM) has a market capitalization of 462.23M USD. This makes CGEM a Small Cap stock.
CULLINAN THERAPEUTICS INC (CGEM) currently has 111 employees.
CULLINAN THERAPEUTICS INC (CGEM) has a resistance level at 8.01. Check the full technical report for a detailed analysis of CGEM support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CGEM does not pay a dividend.
CULLINAN THERAPEUTICS INC (CGEM) will report earnings on 2025-05-20, before the market open.
CULLINAN THERAPEUTICS INC (CGEM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.03).
The outstanding short interest for CULLINAN THERAPEUTICS INC (CGEM) is 15.65% of its float. Check the ownership tab for more information on the CGEM short interest.
ChartMill assigns a technical rating of 1 / 10 to CGEM. When comparing the yearly performance of all stocks, CGEM is a bad performer in the overall market: 92.99% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to CGEM. While CGEM has a great health rating, there are worries on its profitability.
Over the last trailing twelve months CGEM reported a non-GAAP Earnings per Share(EPS) of -3.03. The EPS increased by 17.89% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -26.92% | ||
ROE | -28.35% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 88% to CGEM. The Buy consensus is the average rating of analysts ratings from 16 analysts.